Mobile Heart Rate Variability Biofeedback Improves Autonomic Activation and Subjective Sleep Quality of Healthy Adults – A Pilot Study

Benedict Herhaus1, Adrian Kalin1, Haralampos Gouveris2 and Katja Petrowski1,3*

1 Medical Psychology and Medical Sociology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 2 Sleep Medicine Center and Department of Otolaryngology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 3 Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany

Objective: Restorative sleep is associated with increased autonomous parasympathetic nervous system activity that might be improved by heart rate variability-biofeedback (HRV-BF) training. Hence the aim of this study was to investigate the effect of a four-week mobile HRV-BF intervention on the sleep quality and HRV of healthy adults.

Methods: In a prospective study, 26 healthy participants (11 females; mean age: 26.04 ± 4.52 years; mean body mass index: 23.76 ± 3.91 kg/m²) performed mobile HRV-BF training with 0.1 Hz breathing over four weeks, while sleep quality, actigraphy and HRV were measured before and after the intervention.

Results: Mobile HRV-BF training with 0.1 Hz breathing improved the subjective sleep quality in healthy adults [t(24) = 4.9127, p ≤ 0.001, d = 0.99] as measured by the Pittsburgh Sleep Quality Index. In addition, mobile HRV-BF training with 0.1 Hz breathing was associated with an increase in the time and frequency domain parameters SDNN, Total Power and LF after four weeks of intervention. No effect was found on actigraphy metrics.

Conclusions: Mobile HRV-BF intervention with 0.1 Hz breathing increased the reported subjective sleep quality and may enhance the vagal activity in healthy young adults. HRV-BF training emerges as a promising tool for improving sleep quality and sleep-related symptom severity by means of normalizing an impaired autonomic imbalance during sleep.

Keywords: heart rate variability (HRV), biofeedback (BF), 0.1 Hz breathing, sleep, actigraphy
INTRODUCTION

Around eighty percent of the German working population report having problems falling asleep and/or sleeping through the night (Marschall et al., 2020). For the period from 2010 to 2020, the diagnosis of insomnia rose by sixty percent in the German working population (Marschall et al., 2020). Sleep disorders are related to increased stress reactions, somatic pain, reduced quality of life, emotional stress and mood disorders as well as cognitive, memory and performance deficits (Medic et al., 2017). Besides short term consequences, having sleep disorders over the course of one’s lifetime is associated with the development of arterial hypertension, cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus (Li et al., 2021; Lu et al., 2021; Schipper et al., 2021; Zhang et al., 2021). An ever increasing number of adults are using hypnotics or sedatives to alleviate their disrupted sleep. In a US survey, 4% of the adults aged 20 and over reported using prescription sleep medication during one month (Chong et al., 2013). Most sleep medications have a number of side effects (Watson et al., 2012) and are related to a threefold increased risk of death (Kripke et al., 2012). In recent years, more and more non-pharmacological treatment options, such as cognitive behavioral therapy, proved to be quite effective in the treatment of sleep disorders (Lie et al., 2015; Edinger et al., 2021).

Heart rate variability-biofeedback (HRV-BF) is a form of cardiorespiratory feedback training intervention during which an individual can actively influence autonomous unconscious body processes (Lehrer and Gevirtz, 2014) and is often connected to 0.1 Hz breathing resulting from five seconds inspiration/five seconds expiration. Based on the synchronization of the 0° phase relation between heart rate and breathing (called the highest amplitude of respiratory sinus arrhythmia; RSA) as well as the 180° phase relationship between heart rate, blood pressure, gas exchange efficiency at the alveoli and baroreflex activity are improved by HRV-BF with paced breathing (Lehrer and Gevirtz, 2014). There is evidence that HRV-BF improves the HRV and symptom severity of disorders like hypertension, asthma, and depression (Lehrer et al., 2020).

Interestingly, an association between the HRV as a surrogate marker of autonomic nervous system (ANS) activity and sleep stages has been observed. In healthy individuals, there is a shift from sympathetic to parasympathetic dominance during non-rapid eye movement (non-REM) sleep with a temporary increase in sympathetic system activity during REM sleep (Trinder et al., 2001). Furthermore, the RSA as one mechanism of the HRV-BF has been described as an intrinsic resting function which increases during non-REM sleep (Bonnet and Arand, 1997). These pathways support the hypothesis of playing an important role of parasympathetic dominance for restorative sleep (Hayano and Yasuma, 2003) and of sleep-related vagal activation for promoting anti-inflammatory processes during sleep (Olshansky, 2016). Therefore, it may be argued that HRV-BF with paced breathing both during daytime and before going to sleep may have the potential to improve sleep quality by means of enhancing the baroreflex activity and maximizing the RSA.

Concerning the effect of HRV-BF intervention on sleep quality, four studies have demonstrated an improvement in the sleep quality of different sleep disorders (Lin et al., 2019; Park et al., 2019; Burch et al., 2020; Hasuo et al., 2020). However, only one of them used an objective sleep quality evaluation method, namely actigraphy (Park et al., 2019). The other three studies only assessed sleep-related reported outcomes depicting the respective subjective perceptions of study participants. Due to the fact that the mean age of the participants in three of these studies was greater than sixty years, the reported results may be more relevant in reference to older adults. Given that sleep disorders may be quite prevalent also in the younger adult population (Grobe et al., 2019), and due to the relative paucity of studies on the potential effects of HRV-BF on the sleep quality of healthy adults, further research is needed.

Therefore, in the current study, subjective sleep-related reported outcomes and objective actigraphic metrics of sleep quality as well as HRV during short-term resting conditions were collected prior to and following a four-week mobile HRV-BF intervention with 0.1 Hz breathing in healthy adults. Based on the study by Hasuo et al. (2020) and Lin et al. (2019) who reported an improved subjective sleep quality after HRV-BF and the absence of any effect of paced breathing on polysomnography-based objective outcomes in self-reported good sleepers in the study by Tsai et al. (2015), we hypothesized that HRV-BF with 0.1 Hz breathing would accordingly increase the subjective but not the objective sleep quality in healthy adults (hypothesis 1). Based on the meta-analysis by Lehrer et al. (2020) that showed an HRV increase after HRV-BF in different populations, an HRV improvement after HRV-BF with 0.1 Hz breathing was to be expected in our study cohort as well (hypothesis 2).

MATERIALS AND METHODS

Study Participants

The study participants were recruited through online tendering and notice boards at different universities. After recruitment, study inclusion and exclusion criteria were checked in a standardized interview using the Structured Clinical Interview both for axis I and II (Wittchen et al., 1997). Exclusion criteria were age lower than 18 years and higher than 65 years, BMI lower than 18.5 kg/m² and higher than 27 kg/m², any acute and/or chronic medical illness, mental disorders, medication affecting the heart rate or the central nervous system (e.g., beta blockers), illicit drug abuse, stressful life-events within the previous six months. The prospective participants took part in telephone interviews based on the entire procedure of the Structured Clinical Interview (SCID; Wittchen et al., 1997) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association [APA], 2000).

Study Design

The participants were instructed to perform mobile HRV-BF training with 0.1 Hz breathing at home via an ambulatory HRV-BF training system over the course of four weeks. They were further instructed to train for at least 100 min per week,
including at least five daytime training sessions and five training sessions before going to sleep. At the end of each week of training, the participants were to receive a coaching telephone call to obtain feedback, technical and emotional support from a therapist. The assessment of sleep quality, autonomic activity and well-being took place before and after the four-week-training period. A detailed description of the study design is given in Figure 1. The study protocol was approved by the Ethics Committee of the Local Medical Association (Nr. 2021-16151). All study procedures were in accordance with the Principles of the Declaration of Helsinki for studies with human participants.

**Heart Rate Variability Biofeedback**

The mobile system "eSense Pulse" by Mindfield Biosystems Ltd. (Gronau, Germany) was used for HRV-BF training. The participants wore a chest strap with a small sensor during training and started the training via the eSense app on their smartphone or tablet. During training, a ball that expands (breathe in) and shrinks (breathe out) on the screen specified the breathing frequency goal to a value of six cycles per minute (five seconds inspiration, five seconds expiration). The HRV was visualized by new symbols varying in color depending on the respectively measured values, which appeared every ten seconds. When the participants achieved the specified breathing frequency, resulting in an increased sinus arrhythmia, the symbols appearing on the smartphone display were green. When the participants did not achieve the specified breathing frequency, the symbols appeared in yellow (non-significant deviation), orange (significant deviation), or red (very significant deviation). The participants were instructed to adjust their breathing frequency to reach emergence of as many green symbols as possible for the entire training session. During training, the HRV was measured by a single-channel electrocardiograph (ECG) signal recorded by the chest strap at a sample rate of 500 Hz. At the end of each session, the data were either directly e-mailed from the app to the researcher or saved in the participant’s e-sense account. All data from the app were anonymized. The ECG recordings were analyzed with Kubios software (Kubios Oy, Kuopio, Finland). To eliminate extra beats in the R-R interval, an automatic filtering process method was applied (threshold: 0.45 s).

**Outcomes**

**Heart Rate Variability Measurements**

For the assessment of the ANS activity before and after the training period of four weeks, two short-term measurements were carried out at the medical facility: (1) sitting in an upright position while watching the documentary 'World below the Sea' on the screen for five minutes, and (2) resting condition in supine position for 5 min. A single-channel electrocardiograph (ECG) signal (2 electrodes) with a sample rate of 500/s. was worn during the different measurements. The HRV system HRVScanner™ (BioSign, Ottenhofen, Germany) was used for measurement, analysis and calculation of the heart rate, heart rate variability, and pulse wave velocity. All recorded ECGs (26 participants × 4 measurements = 104) were checked by experienced personnel beat-to-beat. Artifacts were corrected using the deletion method. The rate of losses (number of heartbeats marked as artifact or ectopic beats divided by all heartbeats detected, in%) was <0.06%. HRV was quantified by the following metrics: root mean square successive differences (rMSSD), standard deviation of all NN-intervals (SDNN), total power (TF), power in the very-low frequency range 0.003–0.04 Hz (VLF), power in the low-frequency band 0.04–0.15 Hz (LF), absolute power in the high frequency range 0.15–0.4 Hz (HF) and LF/HF ratio.

**Mental Health**

Mental health-related reported outcomes were assessed using validated established questionnaires. The Short-Form 12 Healthy Survey (SF-12) measures general health and well-being as part of the SF-36 Health Survey (Morfeld et al., 2011). The two components of physical and mental health are calculated. The German version of the Perceived Stress Scale (PSS; Schneider et al., 2020) is used to measure the degree of stressful situations in one’s life during the previous month. Ten items must be answered on a 5-point scale ranging from 1 ‘never’ to 5 ‘very often’. The Brief Symptom Inventory 18 (BSI-18; Franke, 2000) captures physical and psychological complaints of the previous seven days. Based on 18 items on a 5-point scale (from ‘not at all’ to ‘extremely severe’), the dimensions of somatization, depression and anxiety are calculated.
Sleep Quality (Actigraphy & PSQI)
Objective sleep quality was measured using a two-night wrist actigraphy. The participants were instructed to wear the wrist actigraphy on their non-dominant hand. Additionally, the time points of going to sleep, waking up at night, and waking up in the morning were to be marked. Also, sleep diaries were to be kept. Based on actigraphic recordings, total sleep time (TST), sleep onset latency (SOL), number of awakenings (NAW), and waking after sleep onset (WASO) were analyzed. The Motionlogger® (Ambulatory Monitoring Inc., Ardsley, United States) actigraph was used and was set to record data in 10-s epochs. Action-W Version 2.7.3045 software (AW2.7, Ambulatory Monitoring Inc., Ardsley, United States) was used to analyze the sleep patterns.

Subjective sleep quality was measured by the German version of the Pittsburgh Sleep Quality Index (PSQI; Riemann and Backhaus, 1996). This questionnaire assesses sleep quality over a one-month-period using ten items. More specifically, the PSQI measures sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each item is answered on a four-point scale ranging from ‘not at all’ to ‘3 × or more per week’.

Statistical Analysis
Sample size was calculated with the G*power program (version: 3.1.9.2) (Faul et al., 2007). Previous HRV-BF studies demonstrated a small to medium effect size [see meta-analysis by Lehrer et al. (2020)]. Power analysis showed that for an expected medium effect size of Cohen’s $d = 0.5$ for the HRV outcome measure using a dependent $t$-test to prove pre- and post- measurement at a significance level of $p = 0.05$ and power of 80% ($1-\beta = 0.80$), a total sample size of $n = 27$ participants would be needed. The software program used to analyze the data was SPSS Statistics version 23 (IBM, Chicago, IL, United States).

The effects of HRV-BF intervention on heart rate, HRV parameters, psychological measures, and sleep quality were analyzed by a dependent $t$-test. The HRV values were transformed by logarithm naturalis + 1 to obtain approximately normal distributions.

RESULTS
Participants
The data collection from the 27 individuals included in the study was conducted between November 2020 and September 2021. One participant dropped out during the intervention period. The mean age of the 26 healthy participants (15 women and 11 men) was 26.04 ± 4.52 years, and the mean body mass index was 23.76 ± 3.91 kg/m².

Heart Rate Variability-Biofeedback Training
Over the four intervention weeks, the participants on average performed 21.04 (SD = 2.91) daytime training sessions and 20.56 (SD = 3.32) training sessions before going to sleep. The mean training time was 103.80 (SD = 9.56) minutes/week. Figure 2 demonstrates successful HRV-BF training with an increase in the HRV-parameters $\ln + 1$ HF and $\ln + 1$ LF over the course of four weeks.

Mental Health
The self-reported stress perception by the PSS demonstrated significant lower scores after the four weeks’ intervention. With regard to the BSI, the total score, the subscale somatization, and

![Figure 2](image-url)

**FIGURE 2** | Changes in autonomic function showing in HRV-parameters log HF and log LF (M ± SD) during base line and four weeks of intervention with 0.1 Hz breathing. RSB, Resting sitting position with spontaneous breathing; W1, week 1; W2, week 2; W3, week 3; W4, week 4. ***$p \leq 0.001$.**
the subscale depression demonstrated significant lower values after the four weeks’ intervention. In addition, the physical score of SF-12 was significantly improved by the intervention (see Table 1).

Sleep Quality
As shown in Table 2, there were significant improvements in the PSQI total score as well as in the sub-scores sleep quality, sleep latency, and daytime dysfunction after the four weeks’ intervention. Concerning the actigraphy data, the use of a dependent t-test demonstrated no significant differences after the four weeks’ intervention (see Table 2).

Autonomic Function
Concerning the 5-min sitting position, a significant increase in ln + 1 TP and ln + 1 LF could be observed after the four weeks’ intervention. With regard to the 5-minute supine position, there was a significant increase in ln + 1 SDNN, ln + 1 TP, and ln + 1 LF after the four weeks’ intervention (see Table 2).

DISCUSSION
This is the first study to investigate the effect of HRV-BF training on both subjective and objective sleep quality as well as on HRV in healthy adults. HRV-BF training demonstrated an improvement in the subjective sleep quality but not in the objective sleep quality (hypothesis 1) as well as an increase in the number of awakenings (WASO), minutes without sleep latency, and daytime dysfunction after the four weeks’ intervention of HRV-BF training the present study showed an improvement of the subjective sleep quality with an increase in the vagal activity of healthy adults. The lack of effect on the objective sleep quality can be explained by the relatively good pre-interventional sleep patterns of our study cohort who had an average sleep efficiency of 96%. It must be taken in consideration that the effect of HRV-BF on sleep parameters was investigated in good sleepers.

Several studies have demonstrated that HRV-BF training improves different aspects of sleep quality in individuals with depression (Lin et al., 2019), cancer (Burch et al., 2020), overactive bladder syndrome (Park et al., 2019) or caregivers with sleep disturbances (Hasuo et al., 2020). In studies with healthy adults, HRV-BF training showed an increase in the HF component during two-night recordings (Sakakibara et al., 2013). In addition, no effect of paced breathing for 20 min before going to sleep on polysomnography data during the evaluation of two consecutive nights could be observed in self-reported good sleepers (Tsai et al., 2015). After a four-week-intervention of HRV-BF training the present study showed an improvement of the subjective sleep quality with an increase in the vagal activity of healthy adults. The lack of effect on the objective sleep quality can be explained by the relatively good pre-interventional sleep patterns of our study cohort who had an average of approximately 7 1/2 h total sleep time and an average sleep efficiency of 96%. It must be taken in consideration that the effect of HRV-BF on sleep parameters was investigated in good sleepers.

We propose two potential mechanisms by which HRV-BF may improve the sleep quality of healthy adults. First, HRV-BF with 0.1 Hz breathing causes a 0° phase relation between heart oscillations and breathing, resulting in maximal RSA amplitude

| TABLE 1 | BSI, PSS, and SF-12 before and after four weeks intervention of HRV-BF in healthy adults. | Mobile HRV-BF with 0.1 Hz breathing 4-weeks intervention |
|---|---|---|
| BSI | Pre, M (SD) | Post, M (SD) | t | p |
| Total score | 7.20 (6.72) | 5.32 (4.75) | 2.540 | ≤0.05 |
| Subscales | | | 0.01 |
| Somatization | 2.32 (2.90) | 1.40 (1.94) | 3.192 | ≤0.05 |
| Depression | 2.40 (2.72) | 1.32 (1.73) | 2.961 | ≤0.05 |
| Anxiety | 2.48 (2.42) | 2.60 (2.18) | −0.270 | 0.79 |
| PSS | 14.48 (5.23) | 12.20 (6.74) | 2.196 | ≤0.05 |
| SF-12 | | | 0.44 |
| Physical score | 51.83 (7.85) | 55.24 (3.16) | −2.172 | ≤0.05 |
| Mental score | 50.32 (8.99) | 50.86 (8.33) | −0.249 | 0.81 |

BSI, Brief Symptom Inventory; PSS, Perceived Stress Scale; SF, Short Form Health Survey.

| TABLE 2 | Objective and Subjective Sleep Quality before and after four weeks intervention of HRV-BF in healthy adults. | Mobile HRV-BF with 0.1 Hz breathing 4-weeks intervention |
|---|---|---|
| Actigraphy data | Pre, M (SD) | Post, M (SD) | t | p |
| Sleep, minutes | 462 (63) | 461 (50) | 0.042 | 0.97 |
| Awake, minutes | 17 (13) | 18 (15) | −0.071 | 0.94 |
| Sleep, minutes | 444 (62) | 444 (45) | 0.059 | 0.96 |
| %-Sleep | 96 (3) | 96 (3) | −0.234 | 0.82 |
| Sleep Onset Latency, minutes | 3.54 (2.75) | 3.19 (2.64) | 0.693 | 0.50 |
| Number of awakenings | 9.83 (6.18) | 11.04 (8.19) | −0.944 | 0.35 |
| Wake After Sleep Onset (WASO), minutes | 12.73 (10.79) | 12.19 (9.79) | 0.359 | 0.72 |
| PSQI | | | |
| Total score | 5.96 (2.13) | 4.40 (2.15) | 4.927 | ≤0.001 |
| Subscores | | | 0.99 |
| Sleep quality | 1.16 (0.62) | 0.80 (0.50) | 2.823 | ≤0.01 |
| Sleep latency | 1.08 (0.57) | 0.80 (0.41) | 3.055 | ≤0.01 |
| Sleep duration | 0.20 (0.41) | 0.08 (0.28) | 1.365 | 0.19 |
| Habitual sleep efficiency | 0.40 (0.58) | 0.32 (0.63) | 0.700 | 0.49 |
| Sleep disturbances | 0.96 (0.35) | 1.00 (0.00) | −0.569 | 0.57 |
| Use of sleeping medication | 0.16 (0.47) | 0.04 (0.20) | 1.809 | 0.08 |
| Daytime dysfunction | 2.00 (1.08) | 1.36 (1.00) | 3.720 | ≤0.01 |

d=0.99
The RSA is regulated by vagal efferent pathways from the nucleus ambiguus (Yasuma and Hayano, 2004) and is described as an intrinsic resting function which increases during non-REM sleep (Bonnet and Arand, 1997). In contrast, acute psychological stress may reduce parasympathetic dominance (Bertisch et al., 2016; Oliveira-Silva et al., 2020). Interestingly, baroreflex activity also buffers sympathetic activation during sleep, especially during cyclically alternating patterns (Iellamo et al., 2016; Oliveira-Silva et al., 2020). Table 3 depicts the change of heart rate and HRV parameters before and after four weeks intervention of HRV-BF in healthy adults.

### Table 3: Heart rate and HRV-parameters before and after four weeks intervention of HRV-BF in healthy adults.

| Time Position | Parameter | Mobile HRV-BF with 0.1 Hz breathing | 4-weeks intervention | \( \Delta_{\text{Post-Pre}} \) M (SD) | \( t \) | \( p \) |
|---------------|-----------|-----------------------------------|----------------------|--------------------------------.|-------|-----|
| 5-minutes sitting position | Heart rate (b/min) | 72.01 (13.67) | 72.92 (10.95) | 0.91 (7.33) | -0.636 | 0.53 |
|                | rMSSD (ms) | 45.81 (19.69) | 48.59 (24.60) | 2.77 (18.30) | 0.06 (0.39) | 0.279 | 0.47 |
|                | ln + 1 rMSSD* | 3.76 (0.45) | 3.81 (0.42) | 0.06 (0.39) | 0.279 | 0.47 |
|                | SDNN (ms) | 61.50 (19.35) | 70.71 (27.24) | 9.21 (22.43) | 0.12 (0.33) | 0.233 | 0.82 |
|                | ln + 1 SDNN* | 4.09 (0.32) | 4.21 (0.36) | 0.12 (0.33) | 0.233 | 0.82 |
|                | TP (ms\(^2\)) | 1365.16 (836.60) | 2162.47 (2063.04) | 799.31 (1673.52) | 0.32 (0.70) | 0.233 | 0.82 |
|                | ln + 1 TP* | 7.03 (0.63) | 7.35 (0.61) | 0.32 (0.70) | 0.233 | 0.82 |
|                | VLF (ms\(^2\)) | 409.32 (304.19) | 425.81 (343.97) | 16.49 (392.96) | 0.233 | 0.82 |
|                | ln + 1 VLF* | 5.76 (0.74) | 5.80 (0.72) | 0.233 | 0.82 |
|                | LF (ms\(^2\)) | 541.70 (482.47) | 1296.91 (1665.97) | 755.21 (1606.89) | 0.233 | 0.82 |
|                | ln + 1 LF* | 5.99 (0.78) | 6.62 (1.09) | 0.233 | 0.82 |
| 5-minutes supine position | Heart Rate (b/min) | 63.29 (11.46) | 65.07 (9.90) | 1.78 (7.96) | 0.19 | 0.19 |
|                | rMSSD (ms) | 67.93 (47.86) | 74.39 (40.33) | 6.63 (3.09) | 0.19 | 0.19 |
|                | ln + 1 rMSSD* | 4.05 (0.59) | 4.17 (0.48) | 0.12 (0.44) | 0.19 | 0.19 |
|                | SDNN (ms) | 74.39 (40.33) | 85.02 (30.16) | 10.63 (29.54) | 0.12 (0.44) | 0.19 |
|                | ln + 1 SDNN* | 4.22 (0.45) | 4.40 (0.35) | 0.18 (0.36) | 0.19 | 0.19 |
|                | TP (ms\(^2\)) | 2208.46 (2846.68) | 2664.18 (1832.26) | 455.72 (2287.67) | 0.19 | 0.19 |
|                | ln + 1 TP* | 7.28 (0.85) | 7.67 (0.69) | 0.39 (0.74) | 0.19 | 0.19 |
|                | VLF (ms\(^2\)) | 480.09 (341.14) | 423.25 (251.59) | 56.84 (297.35) | 0.19 | 0.19 |
|                | ln + 1 VLF* | 5.92 (0.76) | 5.89 (0.59) | 0.06 (0.66) | 0.19 | 0.19 |
|                | LF (ms\(^2\)) | 992.09 (1952.18) | 1480.89 (1395.26) | 488.80 (1855.95) | 0.19 | 0.19 |
|                | ln + 1 LF* | 7.03 (0.63) | 7.67 (0.61) | 0.39 (0.74) | 0.19 | 0.19 |
|                | HF (ms\(^2\)) | 736.28 (996.26) | 760.04 (1324.38) | 23.76 (902.65) | 0.19 | 0.19 |
|                | ln + 1 HF* | 5.99 (0.78) | 6.10 (0.91) | 0.12 (0.83) | 0.19 | 0.19 |

\( \Delta \), delta values; HF, power in high frequency range 0.15–0.4 Hz; LF, power in low-frequency range 0.04–0.15 Hz; M, mean; rMSSD, root-mean-square successive differences; SD, standard deviation; SDNN, standard deviation of all NN intervals; TP, total power; VLF, power in very low-frequency range 0.003–0.04 Hz.

\( ^* \) values were transformed by logarithm naturalis +1.
The strengths of this pilot study are the rather reliable assessment of the mobile HRV-BF training compliance based on physiological (instead of self-reported) data, the high ECG-data quality with a low rate of losses (<0.06%), and the evaluation of sleep quality with objective and subjective measures. However, several limitations of the current study should be pointed out. Concerning the short-term resting condition and home HRV-BF training, breathing was neither recorded nor checked. Another limitation is the absence of sleep stage classification as an intrinsic drawback of the actigraphy method, which only analyzes sleep-wake cycles. However, it must be considered that actigraphy is a suitable research instrument recommended by the American Academy of Sleep Medicine (AASM) for measuring and evaluating sleep behavior in the home setting. With regard to the shift from sympathetic to parasympathetic dominance during the non-rapid eye movement (non-REM) sleep with a temporary increase in sympathetic system activity during REM sleep cycles, HRV-recordings during sleep before and after the intervention are missing.

In conclusion, the present data suggest that mobile HRV-BF intervention with 0.1 Hz breathing increases the subjective sleep quality and may enhance vagal activity in healthy individuals. In view of the association of impaired sympatho-vagal imbalance in sleep disorders or sleep disturbances, HRV-BF training emerges as a potentially useful treatment option for normalizing the HRV reduction to improve sleep quality and symptom severity in various sleep disorders.

REFERENCES

American Psychiatric Association [APA] (2000). Diagnostic and Statistical Manual of Mental disorders. DSM-IV-TR, 4th Edn. Washington DC: American Psychiatric Association.

Bertisch, S. M., Muresan, C., Schoerling, L., Winkelman, J. W., and Taylor, J. A. (2016). Impact of restless legs syndrome on cardiovascular autonomic control. Sleep 39, 565–571. doi: 10.5665/sleep.5528

Bonnet, M. H., and Arand, D. L. (1997). Heart rate variability: sleep stage, time of night, and arousal influences. Electroencephalogr. Clin. Neurophysiol. 102, 390–396. doi: 10.1016/S0164-4159(96)00444-7

Burch, J. B., Ginsberg, J. P., McLain, A. C., Franco, R., Stokes, S., Susko, K., et al. (2020). Symptom management among cancer survivors: randomized pilot intervention trial of heart rate variability biofeedback. Appl. Psychophysiol. Biofeedback 45, 99–108. doi: 10.1007/s10484-020-09462-3

Chong, Y., Fryer, C. D., and Gu, Q. (2013). Prescription sleep aid use among adults: United States, 2005–2010. NCHS Data Brief 1–8. **VQ.

Edinger, J. D., Arnedt, J. T., Bertisch, S. M., Carney, C. E., Harrington, J. J., Lichstein, K. L., et al. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J. Clin. Sleep Med. 17, 263–298. doi: 10.5664/jcsm.8988

Faul, F., Erdfelder, E., Lang, A.-G., and Buchner, A. (2007). G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175–191. doi: 10.3758/BF03193146

Franke, G. H. (2000). BSI Brief Symptom Inventory - Deutsche Version. Manual. Göttingen: Beltz.

Grohe, G., Steinnmann, S., and Gerr, J. (2019). Gesundheitsreport 2019. Schärfstürzungen. Berlin: Barmer.

Grundy, D. (2002). Neuroanatomy of visceral nociception: vagal and splanchnic afferent. Gut 51, i2–i5. doi: 10.1136/gut.51.suppl_1.i2

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Local Ethics Committee of the Landesärztekammer Rheinland-Pfalz. The participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

BH: conceptualization, methodology, formal analysis, data curation, writing – original draft, and visualization. AK: data curation, and formal analysis. HG: writing – review and editing, and supervision. KP: conceptualization, methodology, writing – review and editing, and supervision. All authors revised the manuscript and approved its final version.

ACKNOWLEDGMENTS

We extend our thanks to psychology student Shiwa Ghassabei for assistance with data collection.
Lie, J. D., Tu, K. N., Shen, D. D., and Wong, B. M. (2015). Pharmacological
treatment of insomnia. P T 40, 759–771.
Lin, I.-M., Fan, S.-Y., Yen, C.-F., Yeh, Y.-C., Tang, T.-C., Huang, M.-F., et al. (2019). Heart rate variability biofeedback increased autonomic activation and improved symptoms of depression and insomnia among patients with major depression disorder. Clin. Psychopharmacol. Neurosci. 17, 222–232. doi: 10.9758/cpn.2019.17.2.222
Lu, M., Wang, Z., Zhan, X., and Yi, W. (2021). Obstructive sleep apnea increases the risk of cardiovascular damage: A systematic review and meta-analysis of imaging studies. Syst. Rev. 10:212. doi: 10.1186/s13643-021-01759-6
Marschall, J., Hildebrandt, S., Kleinlercher, K.-M., and Nolting, H.-D. (2020). Gesundheitsreport 2020. A. Storm Heidelberg: medtomo Verlag GmbH.
Medic, G., Wille, M., and Hemels, M. (2017). Short- and long-term health consequences of sleep disruption. Nat. Sci. Sleep 9, 151–161. doi: 10.2147/SSS.S134864
Morfeld, M., Kirchberger, I., and Bullinger, M. (2011). SF-36. Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe.
Oliveira-Silva, L., Peçanha, T., Fecchio, R. Y., Rezende, R. A., Abreu, A., Silva, G., et al. (2020). Poor sleep quality is associated with cardiac autonomic dysfunction in treated hypertensive men. J. Clin. Hypertens. 22, 1484–1490. doi: 10.1111/jch.13949
Olshansky, B. (2016). Vagus nerve modulation of inflammation: cardiovascular implications. Trends Cardiovasc. Med. 26, 1–11. doi: 10.1016/j.tcm.2015.03.016
Park, J., Park, C. H., Jun, S.-E., Lee, E.-J., Kang, S. W., and Kim, N. (2019). Effects of biofeedback-based sleep improvement program on urinary symptoms and sleep patterns of elderly Korean women with overactive bladder syndrome. BMC Urol. 19:109. doi: 10.1186/s12894-019-0154-0
Polson, J. W., Dampney, R. A. L., Boscan, P., Pickerling, A. E., and Paton, J. F. R. (2007). Differential baroreflex control of sympathetic drive by angiotensin II in the nucleus tractus solitarii. Am. J. Physiol. Integr. Comp. Physiol. 293, R1954–R1960. doi: 10.1152/ajpregu.00041.2007
Riemann, D., and Backhaus, J. (1996). PSQI - Pittsburgher Schlafqualitätsindex. Abstract. Weinheim: Beltz Psychologie Verlage Union.
Sakikabra, M., Hayano, J., Oikawa, L. O., Katsamanis, M., and Lehrer, P. (2013). Heart rate variability biofeedback improves cardiorespiratory resting function during sleep. Appl. Psychophysiol. Biofeedback 38, 265–271. doi: 10.1007/s10843-013-9232-7
Schipper, S. B. J., Van Veen, M. M., Elders, P. J. M., van Straten, A., Van Der Werf, Y. D., Knutson, K. L., et al. (2021). Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 64, 2367–2377. doi: 10.1007/s00125-021-05541-0
Schneider, E. E., Schöpfelder, S., Domke-Wolf, M., and Wessa, M. (2020). Measuring stress in clinical and nonclinical subjects using a German adaptation of the perceived stress scale. Int. J. Clin. Heal. Psychol. 20, 173–181. doi: 10.1016/j.ijchp.2020.03.004
Siepmann, M., Ayakc, V., Unterdörfer, J., Petrowski, K., and Mueck-Weymann, M. (2008). A pilot study on the effects of heart rate variability biofeedback in patients with depression and in healthy subjects. Appl. Psychophysiol. Biofeedback 33, 193–201. doi: 10.1007/s10843-008-9064-z
Trinder, J., Kleiman, J., Carrington, M., Smith, S., Breen, S., Tan, N., et al. (2001). Autonomic activity during human sleep as a function of time and sleep stage. J. Sleep Res. 10, 253–264. doi: 10.1046/j.1365-2869.2001.00263.x
Tsai, H. J., Kuo, T. B. J., Lee, G.-S., and Yang, C. C. H. (2015). Efficacy of paced breathing for insomnia: Enhances vagal activity and improves sleep quality. Psychophysiology 52, 388–396. doi: 10.1111/psyp.12333
Völz, H.-P., Rehbein, G., Triepel, J., Knuepfer, M. M., Stumpf, H., and Stock, G. (1990). Afferent connections of the nucleus centralis amygdalae. Anat. Embryol. (Berl.) 181, 177–194. doi: 10.1007/BF00198957
Watson, C. I., Baghdoyan, H. A., and Lydic, R. (2012). Neuropharmacology of Sleep and Wakefulness. Sleep Med. Clin. 7, 469–486. doi: 10.1016/j.smcl.2012.06.010
Wittchen, H. U., Zaudig, M., and Fydrich, T. (1997). Strukturiertes Klinisches Interview für DSM-IV. Göttingen: Hogrefe.
Yasuma, F., and Hayano, J. (2004). Respiratory sinus arrhythmia. Chest 125, 683–690. doi: 10.1378/chest.125.2.683
Zhang, Y., Jiang, X., Liu, J., Lang, Y., and Liu, Y. (2021). The association between insomnia and the risk of metabolic syndrome: a systematic review and meta-analysis. J. Clin. Neurosci. 89, 430–436. doi: 10.1016/j.jocn.2021.05.039
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Herhaus, Kalin, Gouveris and Petrowski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.